KPC Pharmaceuticals,Inc. (SHA:600422)

China flag China · Delayed Price · Currency is CNY
9.50
+0.01 (0.11%)
Apr 29, 2026, 3:00 PM CST
-42.91%
Market Cap 7.19B
Revenue (ttm) 5.80B
Net Income (ttm) 117.67M
Shares Out 756.98M
EPS (ttm) 0.16
PE Ratio 61.26
Forward PE 22.75
Dividend 0.18 (1.90%)
Ex-Dividend Date Jul 30, 2025
Volume 9,274,391
Average Volume 8,055,381
Open 9.31
Previous Close 9.49
Day's Range 9.31 - 9.54
52-Week Range 9.28 - 16.96
Beta 0.11
RSI 15.41
Earnings Date Apr 25, 2026

About KPC Pharmaceuticals,Inc.

KPC Pharmaceuticals,Inc., a pharmaceutical company, engages in the research and development, production, marketing, and commercial wholesale of botanical drugs and natural drugs in the People’s Republic of China and internationally. It offers artemisia annua series, panax notoginseng, gastrodia, artemether, comether tablets, specialty herbal products, classic prescription for bones and joint, antibiotics, immunosuppressive, oral products, injections, and other products, as well as engages in the wholesale and retail of medicines and equipment. ... [Read more]

Sector Healthcare
Founded 1951
Employees 5,072
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 600422
Full Company Profile

Financial Performance

In 2025, KPC Pharmaceuticals,Inc.'s revenue was 6.58 billion, a decrease of -21.74% compared to the previous year's 8.40 billion. Earnings were 349.94 million, a decrease of -46.00%.

Financial Statements

News

There is no news available yet.